Last reviewed · How we verify
Brilinta
At a glance
| Generic name | Brilinta |
|---|---|
| Sponsor | AstraZeneca |
| Target | Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Acute coronary syndrome
- Myocardial Reinfarction Prevention
- Percutaneous coronary intervention
- Peripheral vascular disease
Common side effects
- Bleeding (PLATO Major + Minor)
- Dyspnea
- Major Bleeding
Serious adverse events
- Fatal/Life-threatening Bleeding
- Intracranial Hemorrhage (Fatal/Life-threatening)
- Fatal Bleeding
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Ticagrelor Monotherapy After Stenting (PHASE2)
- The 10-Year Extended Follow-up of the DACAB Trial
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brilinta CI brief — competitive landscape report
- Brilinta updates RSS · CI watch RSS
- AstraZeneca portfolio CI